NEW YORK, April 12, 2013 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that ProMetic Life Sciences Inc. (OTCQX: PFSCF; TSX: PLI), a global biopharmaceutical corporation, has chosen to trade on OTCQX®, the best OTC marketplace with qualified companies. (Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO) ProMetic Life Sciences Inc. began trading today on OTCQX International, a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies listed on a qualified stock exchange in their home country. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com. "The OTCQX marketplace enables reputable OTC-traded companies to create an information-rich marketplace for their investors," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "We are pleased ProMetic Life Sciences Inc. has chosen to join the other elite companies trading on OTCQX." "More than 50% of our revenues come from U.S. clients and strategic partners; this combined with our growing U.S. based subsidiary, the recent grant of an orphan drug designation by the US FDA as well as various upcoming US IND filings has made it necessary to accommodate the growing demand for our securities from U.S. based investors," mentioned Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic Life Sciences Inc. "Joining OTCQX fits perfectly with our strategy to further develop our presence in the U.S.," added Mr. Laurin. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), will serve as ProMetic Life Sciences Inc.'s Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements. ProMetic Life Sciences Inc. ("ProMetic") ( www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Laval (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia. ProMetic Life Sciences Inc. trades in the U.S. on OTCQX under the symbol "PFSCF."